Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Senetek (SNTK) -- Ignore unavailable to you. Want to Upgrade?

To: Ray who wrote (46)	10/16/2003 7:48:44 PM
From: SemiBull	Read Replies (1) \| Respond to of 101

Senetek PLC and Age Advantage Laboratories, Inc. Announce Signing of Kinetin License Thursday October 16, 6:34 pm ET NAPA, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News), www.senetekplc.com , and Age Advantage Laboratories, Inc., www.ageadvantagelabs.com , today announced the signing of a license agreement for Age Advantage to formulate its unique "Age Eraser" creme with Senetek's patented Kinetin anti-aging compound and market it in the United States to spas, beauty salons, department stores, high-end perfumeries and natural and health product retailers. Frank J. Massino, Chairman and Chief Executive Officer of Senetek, said, "We are very pleased that Age Advantage Laboratories has joined our licensee network. Its strength with high-end day and resort spas and beauty salons will put Kinetin in an ideal esthetician-assisted environment where its unique properties can be optimally presented, and we look forward to pursuing other potential combinations of Kinetin with Age Advantage's superb skin treatment formulations. We are also pleased that this license takes us another step closer to achieving Senetek's goal of making Kinetin-based skin care available to consumers across the full spectrum of retail channels of distribution." Andrew P. Strickman, Chief Executive Officer of Age Advantage Laboratories, said, "We are excited that Senetek has licensed Kinetin for use in Age Advantage Laboratories' 'Age Eraser' skin creme. 'Age Eraser' is a vital part of our skin repair regimen and we believe that the combination of our ingredients with Kinetin clearly makes this the most advanced anti-aging product on the market. With this new alliance, we also hope to develop other products which combine Kinetin with our state of the art formulations. Our goal is to fight the aging process, and Kinetin, a plant-derived compound, moves us toward achieving that goal by helping to prevent the signs and symptoms of premature skin aging and slowing the aging process of the cells, naturally and without irritation." Age Eraser from Age Advantage Laboratories has received significant praise from beauty experts such as Kat James. Author of "The Truth About Beauty," James writes, "This is one of the most impressive Kinetin products I've found." Senetek's patented ingredient, Kinetin, is a naturally occurring cytokinin that has proven to be effective in treating the appearance of aging skin with virtually none of the side effects associated with acid-based active ingredients. Senetek's ten other licensees include ICN Pharmaceuticals, Inc., Revlon, Inc. and The Body Shop, which have successfully introduced Kinetin in their respective channels of distribution. Headquartered in Atlanta, Georgia, Age Advantage Laboratories offers natural anti-aging and skin repair products that deliver solutions for outer beauty and inner health, principally through natural food stores, pharmacies, specialty stores, spas and salons nationwide. Visit Senetek PLC's Web site: senetekplc.com Senetek PLC Investor Relations Contact: 1-707-226-3900 ext. 102 E-Mail: Pknopick@eandecommunications.com Visit Age Advantage Laboratories' Web site: ageadvantagelabs.com Age Advantage Laboratories' Investor Relations Contact 1-212-966-0024 E-Mail: walter@trentandcompany.com Safe Harbor Statement: This news release may contain statements that may be considered "forward-looking statements" under the federal securities laws, including statements concerning the eventual national roll-out of the infomercial, the potential success of the Kinetin Plus product line and the hoped-for benefits of this product launch. Forward-looking statements by their nature involve substantial uncertainty and there can be no assurance that actual results or events will not differ materially from those described in the forward-looking statements as a result of various factors, including the risks and uncertainties described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2002 and Quarterly Reports on Form 10-Q for subsequent calendar quarters of 2003, filed with the Securities and Exchange Commission. In addition, while the Company has attempted to identify in those filings the principal factors that it believes could result in such material differences, there can be no assurance that it has identified all of such factors or all of the ways in which such factors may affect future results or events. Source: Senetek PLC